Intra-Cellular Therap(ITCI.US)

Event Tracking

Nov6

Johnson & Johnson's Caplyta Approved for Severe Depression as Adjunctive Therapy

12:30

Apr6

Intra-Cellular Therapies Receives 'Hold' Rating, Analysts Adjust Ratings

06:10

Apr1

Johnson & Johnson Expected to Complete Acquisition of Intra-Cellular Therapies by April 2, 2025

20:11

Mar30

Intra-Cellular Therapies, Inc. Receives Consensus Hold Recommendation from Fifteen Research Firms with Target Price of $106.08

06:52

Mar18

Shareholders of Intra-Cellular Therapies Inc File Lawsuit in New York Supreme Court

21:53

Feb22

Intra-Cellular Therapies released FY2024 Annual Earnings on February 21 (EST), actual revenue $680.85M (forecast $674.97M), actual EPS -$0.724 (forecast -$0.7164)

04:00

Schedules & Filings

Schedules

Filings

Feb21

Earning Release(EST)

FY2024 Q4 Earning Release (USD) Revenue 199.22 M, Net Income -16.89 M, EPS -0.1591

Oct30

Earning Release(EST)

FY2024 Q3 Earning Release (USD) Revenue 175.38 M, Net Income -26.32 M, EPS -0.2488

Aug7

Earning Release(EST)

FY2024 Q2 Earning Release (USD) Revenue 161.39 M, Net Income -16.22 M, EPS -0.1563

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change